MGC Pharma advances Covid-19 trial
MGC Pharmaceuticals (ASX:MXC) continues to advance its clinical research on a Covid-19 treatment – ArtemiC – with a Phase II trial recruiting its first patients.
The study is being conducted at various trial sites in Israel and India, with 33 out of 50 patients being treated or recruited to participate across all sites to date. This follows the release of interim trial results in August indicating significant efficacy for Covid-19.
The product, ArtemiC, containing artemisinin, curcumin, boswellia serrata and vitamin-C, is intended to treat Covid-19 by preventing the cytokine storm, where the bodies immune system goes into hyperdrive and starts attacking healthy cells, causing the catastrophic symptoms of the virus.
With the study launching at Mahatma Gandhi Mission’s Medical College & Hospital (MGM Hospital) in India, it is expected that high numbers of Covid-19 in the country will allow recruitment to be completed quickly with results expected to be available in November.
Covid-19 has taken a foothold in India, with 646,263 new cases reported in the last 7 days, and as at 21 September 2020 the World Health Organisation’s (WHO) situation report taking the total cases in India to 5,400,619, with over 86,752 deaths.
The Chief Scientific Officer at Oz Innovative Solutions Pty Ltd, Dr Prabhakar Ranjekar, said “We are pleased to associate with MGC Pharmaceuticals and commence recruitment of Covid-19 patients in India. Currently, India is the second most affected country by COVID-19 and a successful trial of ArtemiC will provide a better treatment option for the doctors.”